Drug Trial Radar · NCT01952444
Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Apr 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Oct 29, 2013
Primary completion
Apr 9, 2014
Study completion Apr 9, 2014
Sponsor
- Lead sponsor
- Elusys TherapeuticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 30, 2013
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Evaluate the safety, tolerability and pharmacokinetics (PK) of intravenous (IV) ETI-204 alone and in the presence of IV and oral ciprofloxacin
Conditions
- Inhalational Anthrax
Interventions
ETI-204Biological
A single IV infusion of 16 mg/kg ETI-204 over 90 minutes on Day 1
CiprofloxacinDrug
A single IV Infusion of 400 mg Ciprofloxacin over 60 minutes immediately following the infusion of ETI-204 on Day 1, followed by oral Ciprofloxacin (750 mg every 12 hours) on Days 2-8, and a final oral dose on the morning of Day 9.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Adverse EventsTime frame: Up to 71 days or 101 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each group.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quintiles
Overland Park, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.